3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
2
Unknown
1
Terminated
1
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Dermatologic
1
Conditions
Melanoma
9
Carcinoma, Non-Small-Cell Lung
9
Carcinoma, Renal Cell
8
Triple Negative Breast Neoplasms
5
Neoplasm Metastasis
5
Squamous Cell Carcinoma of Head and Neck
4
Pancreatic Neoplasms
4
Colorectal Neoplasms
4
Stomach Neoplasms
3
Ovarian Neoplasms
3
Neoplasms
2
Lymphoma
2
Head and Neck Neoplasms
2
Glioblastoma
2
Gastrointestinal Stromal Tumors
2
Esophageal Squamous Cell Carcinoma
2
Esophageal Neoplasms
2
von Hippel-Lindau Disease
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Spinocerebellar Degenerations
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pheochromocytoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Interventions
Doxorubicin
13
Gemcitabine
10
Cyclophosphamide
10
pazopanib
8
Filgrastim
8
Radiotherapy
7
Ifosfamide
7
Cisplatin
7
Irinotecan
6
Docetaxel
6
Radiation
5
Granulocyte Colony-Stimulating Factor
5
Etoposide
5
Trabectedin
4
Magnetic Resonance Spectroscopy
4
Celecoxib
4
Busulfan
4
Bevacizumab
4
Albumin-Bound Paclitaxel
4
temsirolimus
3
sargramostim
3
pembrolizumab
3
X-Rays
3
Sirolimus
3
Radiotherapy, Intensity-Modulated
3
Paclitaxel
3
Neoadjuvant Therapy
3
Leucovorin
3
Dexrazoxane
3
Cryosurgery
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Sarcoma
×
spartalizumab
×
Clear all
NCT03009058
2024-11-25
MODULATE
Immodulon Therapeutics Ltd
Phase 1/2
Terminated
2 enrolled
7 charts